The presence of a second, specific estrogen binding site in human breast cancer

Walter B. Panko, Cheryl S. Watson, James H. Clark

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Cytosol from human breast cancer was used in saturation analysis over a wide range of [3H]-estradiol concentrations. Hydroxylapatite was used to measure specific ligand binding. This type of saturation analysis demonstrated the presence of a second, specific estrogen binding site, named type II estrogen binding site, in human breast cancer cytosol. Type II estrogen binding sites have a low affinity (Kd = 80 nM vs 0.31 nM) but a higher concentration (200 fmol/mg cytosol protein vs 30.3fmol/mg cytosol protein) than the classical cytoplasmic estrogen receptor. The presence of type II estrogen binding site in human breast cancer cytosol was confirmed by a "post-labeled" sucrose gradient method. Type II estrogen binding site was shown to bind only to estrogens and was found only in estrogen target tissue. Individual tumors were examined for the presence of type II estrogen binding sites and 23 25 (92%) contained significant amounts of these sites, including six which lacked estrogen receptor. The concentration of type II estrogen binding site was strongly correlated to the concentration of cytoplasmic estrogen receptor. We conclude that human breast cancer cytosol contains a specific, secondary estrogen binding site, similar to that previously described in the rat uterus. Knowledge about this type II estrogen binding site may provide us with additional information on the mechanisms of hormonally-dependent growth in breast cancer.

Original languageEnglish (US)
Pages (from-to)1311-1316
Number of pages6
JournalJournal of Steroid Biochemistry
Volume14
Issue number12
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Estrogens
Cytosol
Binding Sites
Breast Neoplasms
Estrogen Receptors
Cytoplasmic and Nuclear Receptors
Gradient methods
Durapatite
type II estrogen binding site
Uterus
Sucrose
Rats
Tumors
Estradiol
Proteins
Tissue
Ligands
Growth
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

The presence of a second, specific estrogen binding site in human breast cancer. / Panko, Walter B.; Watson, Cheryl S.; Clark, James H.

In: Journal of Steroid Biochemistry, Vol. 14, No. 12, 1981, p. 1311-1316.

Research output: Contribution to journalArticle

Panko, Walter B. ; Watson, Cheryl S. ; Clark, James H. / The presence of a second, specific estrogen binding site in human breast cancer. In: Journal of Steroid Biochemistry. 1981 ; Vol. 14, No. 12. pp. 1311-1316.
@article{4f62dd97216c4b19a21d90639f8a3248,
title = "The presence of a second, specific estrogen binding site in human breast cancer",
abstract = "Cytosol from human breast cancer was used in saturation analysis over a wide range of [3H]-estradiol concentrations. Hydroxylapatite was used to measure specific ligand binding. This type of saturation analysis demonstrated the presence of a second, specific estrogen binding site, named type II estrogen binding site, in human breast cancer cytosol. Type II estrogen binding sites have a low affinity (Kd = 80 nM vs 0.31 nM) but a higher concentration (200 fmol/mg cytosol protein vs 30.3fmol/mg cytosol protein) than the classical cytoplasmic estrogen receptor. The presence of type II estrogen binding site in human breast cancer cytosol was confirmed by a {"}post-labeled{"} sucrose gradient method. Type II estrogen binding site was shown to bind only to estrogens and was found only in estrogen target tissue. Individual tumors were examined for the presence of type II estrogen binding sites and 23 25 (92{\%}) contained significant amounts of these sites, including six which lacked estrogen receptor. The concentration of type II estrogen binding site was strongly correlated to the concentration of cytoplasmic estrogen receptor. We conclude that human breast cancer cytosol contains a specific, secondary estrogen binding site, similar to that previously described in the rat uterus. Knowledge about this type II estrogen binding site may provide us with additional information on the mechanisms of hormonally-dependent growth in breast cancer.",
author = "Panko, {Walter B.} and Watson, {Cheryl S.} and Clark, {James H.}",
year = "1981",
doi = "10.1016/0022-4731(81)90337-X",
language = "English (US)",
volume = "14",
pages = "1311--1316",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - The presence of a second, specific estrogen binding site in human breast cancer

AU - Panko, Walter B.

AU - Watson, Cheryl S.

AU - Clark, James H.

PY - 1981

Y1 - 1981

N2 - Cytosol from human breast cancer was used in saturation analysis over a wide range of [3H]-estradiol concentrations. Hydroxylapatite was used to measure specific ligand binding. This type of saturation analysis demonstrated the presence of a second, specific estrogen binding site, named type II estrogen binding site, in human breast cancer cytosol. Type II estrogen binding sites have a low affinity (Kd = 80 nM vs 0.31 nM) but a higher concentration (200 fmol/mg cytosol protein vs 30.3fmol/mg cytosol protein) than the classical cytoplasmic estrogen receptor. The presence of type II estrogen binding site in human breast cancer cytosol was confirmed by a "post-labeled" sucrose gradient method. Type II estrogen binding site was shown to bind only to estrogens and was found only in estrogen target tissue. Individual tumors were examined for the presence of type II estrogen binding sites and 23 25 (92%) contained significant amounts of these sites, including six which lacked estrogen receptor. The concentration of type II estrogen binding site was strongly correlated to the concentration of cytoplasmic estrogen receptor. We conclude that human breast cancer cytosol contains a specific, secondary estrogen binding site, similar to that previously described in the rat uterus. Knowledge about this type II estrogen binding site may provide us with additional information on the mechanisms of hormonally-dependent growth in breast cancer.

AB - Cytosol from human breast cancer was used in saturation analysis over a wide range of [3H]-estradiol concentrations. Hydroxylapatite was used to measure specific ligand binding. This type of saturation analysis demonstrated the presence of a second, specific estrogen binding site, named type II estrogen binding site, in human breast cancer cytosol. Type II estrogen binding sites have a low affinity (Kd = 80 nM vs 0.31 nM) but a higher concentration (200 fmol/mg cytosol protein vs 30.3fmol/mg cytosol protein) than the classical cytoplasmic estrogen receptor. The presence of type II estrogen binding site in human breast cancer cytosol was confirmed by a "post-labeled" sucrose gradient method. Type II estrogen binding site was shown to bind only to estrogens and was found only in estrogen target tissue. Individual tumors were examined for the presence of type II estrogen binding sites and 23 25 (92%) contained significant amounts of these sites, including six which lacked estrogen receptor. The concentration of type II estrogen binding site was strongly correlated to the concentration of cytoplasmic estrogen receptor. We conclude that human breast cancer cytosol contains a specific, secondary estrogen binding site, similar to that previously described in the rat uterus. Knowledge about this type II estrogen binding site may provide us with additional information on the mechanisms of hormonally-dependent growth in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019820154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019820154&partnerID=8YFLogxK

U2 - 10.1016/0022-4731(81)90337-X

DO - 10.1016/0022-4731(81)90337-X

M3 - Article

C2 - 7329065

AN - SCOPUS:0019820154

VL - 14

SP - 1311

EP - 1316

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 12

ER -